Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.

You may also be interested in...



Repros' Hypogonadism Treatment Enclomiphene Heads To FDA Panel

Efficacy and safety data for drug, formerly known as Androxal, will be vetted by FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Nov. 3.

Repros’ Androxal Primed For NDA Submission, But Outcomes Study Looms

The testosterone drugmaker is confident that Androxal can gain approval and is on track to submit a filing with FDA this year, but a cardiovascular outcomes study is still on the table.

Repros’ Androxal Primed For NDA Submission, But Outcomes Study Looms

The testosterone drugmaker is confident that Androxal can gain approval and is on track to submit a filing with FDA this year, but talk of a cardiovascular outcomes study is still on the table.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel